NIH Needs To Reconcile Differing Clinical Trial Registry Expectations
This article was originally published in The Gray Sheet
Executive Summary
The National Institutes of Health is trying to reconcile new clinical trial registry requirements for medical devices under the recently enacted FDA Amendments Act with the existing policy of leading medical journal editors
You may also be interested in...
ClinicalTrials.gov Requirements Continue To Baffle Firms And Feds Alike
Device companies are not the only ones tripped up by the new ClinicalTrials.gov trial registration requirements, as FDA, NIH and others struggle to define what is and is not subject to the law
ClinicalTrials.gov Requirements Continue To Baffle Firms And Feds Alike
Device companies are not the only ones tripped up by the new ClinicalTrials.gov trial registration requirements, as FDA, NIH and others struggle to define what is and is not subject to the law
Firms Should Establish Internal Policies For Trial Registry Requirements
Companies should develop internal policies in coordination with FDA about how they are going to comply with new clinical trial registration requirements until more formal rulemaking and guidance are available, according to Rebecca Williams, assistant director of the National Institutes of Health 1ClinicalTrials.gov